Risk factors for mortality in hemodialysis patients: Two-year follow-up study

Disease Markers

Volumn 35, Issue 6, 2013, Pages 791-798

  Sameiro Faria, Maria Do ^a,b   Ribeiro, Sandra ^a,c   Costa, Elísio ^a,c   Mendonça, Denisa ^a   Teixeira, Laetitia ^a   Rocha Pereira, Petronila ^c,d   Fernandes, João ^c,e   Nascimento, Henrique ^a,c   Kohlova, Michaela ^d   Reis, Flávio ^d   Amado, Leonilde ^b   Bronze Da Rocha, Elsa ^a,c   Miranda, Vasco ^b   Quintanilha, Alexandre ^a,c   Belo, Luís ^a,c   Santos Silva, Alice ^a,c  

^a UNIVERSITY OF PORTO   (Portugal)

^b Nephrocare Portugal   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^e UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE 1; C REACTIVE PROTEIN; D DIMER; FERRITIN; HEMOGLOBIN; HEPCIDIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; IRON; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRANSFERRIN; TRANSFERRIN RECEPTOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CENTRAL VENOUS CATHETER; COMORBIDITY; CONTROLLED STUDY; END STAGE RENAL DISEASE; ENDOTHELIAL DYSFUNCTION; FEMALE; FOLLOW UP; HEMATOCRIT; HEMODIALYSIS PATIENT; HUMAN; IRON METABOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; VASCULAR ACCESS;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RISK FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84896956566     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2013/518945     Document Type: Article

References (32)

1. Vollmer W. M., Wahl P. W., Blagg C. R., Survival with dialysis and transplantation in patients with end-stage renal disease. The New England Journal of Medicine 1983 308 26 1553 1558 2-s2.0-0020546455
2. Held J. P., Brunner F., Odaka M., Garcia J. R., Port F. K., Gaylin D. S., Five-year survival for end-stage renal disease patients in the United States, Europe, and Japan, 1982 to 1987. American Journal of Kidney Diseases 1990 15 5 451 457 2-s2.0-0025341013
3. Jager K. J., Lindholm B., Goldsmith D., Fliser D., Wiecek A., Suleymanlar G., Ortiz A., Massy Z., Martinez-Castelao A., Agarwal R., Blankestijn P. J., Covic A., London G., Zoccali C., Dekker F. W., Cardiovascular and non-cardiovascular mortality in dialysis patients: where is the link? Kidney International Supplements 2011 1 21 23
4. Foley R. N., Parfrey P. S., Sarnak M. J., Clinical epidemiology of cardiovascular disease in chronic renal disease. American Journal of Kidney Diseases 1998 32 5, supplement 3 S112 S119 2-s2.0-0031733696
5. Sarnak M. J., Levey A. S., Schoolwerth A. C., Coresh J., Culleton B., Hamm L. L., McCullough P. A., Kasiske B. L., Kelepouris E., Klag M. J., Parfrey P., Pfeffer M., Raij L., Spinosa D. J., Wilson P. W., Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003 108 17 2154 2169 2-s2.0-0141468244 10.1161/01.CIR.0000095676. 90936.80
6. Collins A. J., Cardiovascular mortality in end-stage renal disease. American Journal of the Medical Sciences 2003 325 4 163 167 2-s2.0-0037390117 10.1097/00000441-200304000-00002
7. Stenvinkel P., Carrero J. J., Axelsson J., Lindholm B., Heimbürger O., Massy Z., Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clinical Journal of the American Society of Nephrology 2008 3 2 505 521 2-s2.0-42549131781 10.2215/CJN.03670807
8. Kendrick J., Chonchol M. B., Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nature Clinical Practice Nephrology 2008 4 12 672 681 2-s2.0-56749158017 10.1038/ncpneph0954
9. Costa E., Rocha S., Rocha-Pereira P., Castro E., Reis F., Teixeira F., Miranda V., Faria M. D. S., Loureiro A., Quintanilha A., Belo L., Santos-Silva A., Cross-talk between inflammation, coagulation/fibrinolysis and vascular access in hemodialysis patients. Journal of Vascular Access 2008 9 4 248 253 2-s2.0-60549110919
10. American Diabetes Association, Standards of medical care in diabetes-2009. Diabetes Care 2009 32 S13 S61
11. JNC 6. National High Blood Pressure Education Program, The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Archives of Internal Medicine 1997 157 21 2413 2446 2-s2.0-0030713021
12. Locatelli F., Aljama P., Bárány P., Canaud B., Carrera F., Eckardt K.-U., Hörl W. H., Macdougal I. C., Macleod A., Wiecek A., Cameron S., Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrology, Dialysis, Transplantation 2004 19 supplement 2 1 47 2-s2.0-4344581912
13. Cooper B. A., Branley P., Bulfone L., Collins J. F., Craig J. C., Fraenkel M. B., Harris A., Johnson D. W., Kesselhut J., Li J. J., Luxton G., Pilmore A., Tiller D. J., Harris D. C., Pollock C. A., A randomized, controlled trial of early versus late initiation of dialysis. The New England Journal of Medicine 2010 363 7 609 619 2-s2.0-77956629018 10.1056/NEJMoa1000552
14. Shastri S., Tangri N., Tighiouart H., Beck G. J., Vlagopoulos P., Ornt D., Eknoyan G., Kusek J. W., Herzog C., Cheung A. K., Sarnak M. J., Predictors of sudden cardiac death: a competing risk approach in the hemodialysis study. Clinical Journal of the American Society of Nephrology 2012 7 1 123 130 2-s2.0-84857082805 10.2215/CJN.06320611
15. Zimmermann J., Herrlinger S., Pruy A., Metzger T., Wanner C., Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney International 1999 55 2 648 658 2-s2.0-0032935896 10.1046/j.1523-1755.1999.00273.x
16. Dhingra R. K., Young E. W., Hulbert-Shearon T. E., Leavey S. F., Port F. K., Type of vascular access and mortality in U.S. hemodialysis patients. Kidney International 2001 60 4 1443 1451 2-s2.0-0034786004 10.1046/j.1523-1755.2001. 00947.x
17. Pastan S., Soucie J. M., McClellan W. M., Vascular access and increased risk of death among hemodialysis patients. Kidney International 2002 62 2 620 626 2-s2.0-0035991564 10.1046/j.1523-1755.2002.00460.x
18. Owen W. F. Jr., Lew N. L., Liu Y., Lowrie E. G., Lazarus J. M., The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. The New England Journal of Medicine 1993 329 14 1001 1006 2-s2.0-0027491558 10.1056/NEJM199309303291404
19. Kalantar-Zadeh K., Kilpatrick R. D., Kuwae N., McAllister C. J., Alcorn H. Jr., Kopple J. D., Greenland S., Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction. Nephrology Dialysis Transplantation 2005 20 9 1880 1888 2-s2.0-24044489592 10.1093/ndt/gfh941
20. Costa E., Lima M., Alves J. M., Rocha S., Rocha-Pereira P., Castro E., Miranda V., Faria M. D. S., Loureiro A., Quintanilha A., Belo L., Santos-Silva A., Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy. Journal of Clinical Immunology 2008 28 3 268 275 2-s2.0-43049125082 10.1007/s10875-007-9168-x
21. Costa E., Pereira B. J. G., Rocha-Pereira P., Rocha S., Reis F., Castro E., Teixeira F., Miranda V., Do Sameiro Faria M., Loureiro A., Quintanilha A., Belo L., Santos-Silva A., Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients. American Journal of Nephrology 2008 28 4 677 683 2-s2.0-45149099284 10.1159/000121478
22. Bazeley J., Bieber B., Li Y., Morgenstern H., de Sequera P., Combe C., Yamamoto H., Gallagher M., Port F. K., Robinson B. M., C-reactive protein and prediction of 1-year mortality in prevalent hemodialysis patients. Clinical Journal of the American Society of Nephrology 2011 6 10 2452 2461 2-s2.0-80053911895 10.2215/CJN.00710111
23. Libetta C., Sepe V., Esposito P., Galli F., Dal Canton A., Oxidative stress and inflammation: implications in uremia and hemodialysis. Clinical Biochemistry 2011 44 14-15 1189 1198 2-s2.0-80052921322 10.1016/j.clinbiochem. 2011.06.988
24. Jacober M. L. V., Mamoni R. L., Lima C. S. P., Dos Anjos B. L., Grotto H. Z. W., Anaemia in patients with cancer: role of inflammatory activity on iron metabolism and severity of anaemia. Medical Oncology 2007 24 3 323 329 2-s2.0-36248998247 10.1007/s12032-007-0009-9
25. Fleming R. E., Sly W. S., Hepcidin: a putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease. Proceedings of the National Academy of Sciences of the United States of America 2001 98 15 8160 8162 2-s2.0-0035902586 10.1073/pnas.161296298
26. Wrighting D. M., Andrews N. C., Interleukin-6 induces hepcidin expression through STAT3. Blood 2006 108 9 3204 3209 2-s2.0-33751175421 10.1182/blood-2006-06-027631
27. Tanner R. M., Brown T. M., Muntner P., Epidemiology of obesity, the metabolic syndrome, and chronic kidney disease. Current Hypertension Reports 2012 14 152 159
28. Kalantar-Zadeh K., Abbott K. C., Salahudeen A. K., Kilpatrick R. D., Horwich T. B., Survival advantages of obesity in dialysis patients. American Journal of Clinical Nutrition 2005 81 3 543 554 2-s2.0-15744384336
29. Kalaitzidis R. G., Siamopoulos K. C., The role of obesity in kidney disease: recent findings and potential mechanisms. International Urology and Nephrology 2011 43 3 771 784 2-s2.0-80555126827 10.1007/s11255-011-9974-1
30. Fantuzzi G., Adipose tissue, adipokines, and inflammation. Journal of Allergy and Clinical Immunology 2005 115 5 911 920 2-s2.0-18144408371 10.1016/j.jaci.2005.02.023
31. Fantuzzi G., Adiponectin and inflammation: consensus and controversy. Journal of Allergy and Clinical Immunology 2008 121 2 326 330 2-s2.0-39149088929 10.1016/j.jaci.2007.10.018
32. Mertens A. N. N., Holvoet P., Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB Journal 2001 15 12 2073 2084 2-s2.0-0034804981 10.1096/fj.01-0273rev